pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
Nanopac · news · pharmadog
← back to Nanopac
News mentioning Nanopac
19
stories
May 31, 26
Ultra-low doses could bring costly cancer treatments to more patients in poorer countries
stat
May 13, 26
Immunotherapy Advances in Upfront SCAC Expose Need for Better Second-Line Strategies
onclive
May 10, 26
Five Under 5: Top Oncology Videos for the Week of 5/3
onclive
May 8, 26
Dr Randall on Long-Term Responses and Functional Benefits With Pimicotinib in TGCT
onclive
May 8, 26
Dr Sznol on the Nuances of Recommending Neoadjuvant Therapy in Metastatic Melanoma
onclive
May 8, 26
Dr Gruenbaum on Where Alternative Options to BTK Inhibitors Stand in MCL
onclive
May 7, 26
Dr Sznol on Optimal Treatment Sequencing in Melanoma
onclive
May 7, 26
Dr Mauro on the Significance of Alternative TKI Formulations in CML
onclive
May 7, 26
Dr Olawaiye on the FDA Approval of Relacorilant Plus Nab-Paclitaxel in PROC
onclive
May 6, 26
Neoadjuvant T-DXd Followed by THP Improves RCB in HER2+ Breast Cancer
onclive
May 6, 26
Dr Chari on Frontline Combinations and Transplant Approaches in Multiple Myeloma
onclive
May 6, 26
Dr Herrera on the Significance of the FDA Approval of Nivolumab Plus AVD for Classical Hodgkin Lymphoma
onclive
May 6, 26
Dr Sznol on Biomarkers of Response in Metastatic Melanoma
onclive
May 6, 26
Dr Pant on the Mechanism of Action of Daraxonrasib in PDAC
onclive
May 5, 26
Dr Cohen on Frontline Chemotherapy Selection in Metastatic Pancreatic Cancer
onclive
May 5, 26
Dr Pant on Managing Toxicities With Daraxonrasib in PDAC
onclive
May 5, 26
Breast Cancer Experts Preview Abstracts to Watch at the 2026 ESMO Breast Cancer Congress
onclive
May 5, 26
Dr McGregor on Key End Points of the STRIKE Trial of Tivozanib Plus Pembrolizumab in RCC
onclive
May 5, 26
Dr Kuykendall on the Evolving JAK Inhibitor and Transplant Considerations in Myelofibrosis
onclive
